http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2199805-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ebb6a553affdc364c91cffe3baf12564 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S435-975 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-8142 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S435-974 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6811 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-37 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1048 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-37 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 |
| filingDate | 1995-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9bfbda6f3e70117db9ac3ad5e532f6ee http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_142f9632ecd3b6742b1526f0c02ba754 |
| publicationDate | 1996-03-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2199805-A1 |
| titleOfInvention | In vitro method for predicting the evolutionary response of hiv protease to a drug targeted thereagainst |
| abstract | An in vitro method for identifying distinct, first generation, drug-resistant, biologically active, HIV protease mutants that may emerge in vivo in response to a drug targeted thereagainst comprising: (a) preparing, in the presence of the drug, a library of all first-generation mutants of the protease differing therefrom by one to three amino acid substitutions, each of the protease mutants being generated as part of a polyprotein with reverse transcriptase; (b) isolating drug-resistant, biologically-active mutant proteases by assaying for activity of the reverse transcriptase; and (c) identifying the distinct amino acid changes leading to the drug-resistance of the active, mutant proteases so isolated. An in vitro method for evaluating the efficacy of a drug against a biologically active mutant or wild-type form of HIV protease comprising combining the drug and a mutant polyprotein, comprising an inactive HIV protease, HIV reverse transcriptase, and one or more protease cleavage sites, adding biologically-active mutant or wild-type protease, assaying for release of active reverse transcriptase, whereby reverse transcriptase activity indicates that the drug is not efficacious against the mutant or wildtype form of HIV protease tested. |
| priorityDate | 1994-09-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 282.